Business Context and Reporting Period
This Form 8-K Current Report was filed by Alto Neuroscience, Inc. on May 21, 2024. The filing discloses the appointment of Michael Hanley as Chief Operating Officer, effective May 20, 2024. The Company is an emerging growth company incorporated in Delaware.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. This report focuses exclusively on executive compensation and appointment details.
Material Changes
The primary material change is the addition of Michael Hanley to the executive leadership team as Chief Operating Officer. Mr. Hanley brings prior experience as Chief Business Officer and Chief Commercial Officer at Aeglea BioTherapeutics, Inc., and Vice President and U.S. Chief Commercial Officer at Esteve Pharmaceuticals, S.A.
Compensation, Outlook, and Risks
Compensation Arrangements:
- Base Salary: $470,000 annually, subject to Board adjustment.
- Performance Bonus: Eligible for an annual bonus of up to 40% of base salary, prorated for days employed.
- Equity Grant: Option to purchase 188,000 shares of common stock at fair market value on the grant date.
- Vesting Schedule: 25% vests on the one-year anniversary of the commencement date; the remaining 75% vests monthly (1/48th per month) thereafter, contingent on continuous service.
Termination Provisions:
- Without Cause: Entitles Mr. Hanley to nine months of salary continuation and nine months of COBRA coverage.
- Change in Control (Within 60 days prior or 12 months following): Entitles Mr. Hanley to 12 months of salary continuation, 12 months of target bonus, and accelerated vesting of all outstanding equity awards.
Risks and Contingencies: The filing notes that the summary of the Employment Letter is not complete and is subject to the full agreement. No specific business risks or contingencies regarding the Company's operations are detailed in this specific filing.
Investor Verification Checklist
- Verify the total number of outstanding options granted to Mr. Hanley (188,000) against the Company's total authorized share pool.
- Review the full text of the Employment Letter (referenced as Exhibit 10.8/10.9 in prior S-1 filings) for specific definitions of "Cause" and "Good Reason."
- Confirm the fair market value of the stock on the grant date (May 20, 2024) to determine the exercise price of the options.
- Assess the impact of the new COO's commercial background on the Company's current clinical development and commercialization strategy.